All participants were grouped according to the priming EV71 vaccine formulations ( 160U , 320U , and 640U with adjuvant and 640 U without adjuvant ) and then randomly assigned ( ratio , 2:1 ) to receive a booster dose of vaccine or placebo within each formulation group .